Hemostemix Inc. (CVE:HEM – Get Free Report) shares reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as C$0.10 and last traded at C$0.08, with a volume of 155000 shares. The stock had previously closed at C$0.09.
Hemostemix Trading Down 11.1 %
The company has a market capitalization of C$6.97 million, a PE ratio of -4.50 and a beta of 0.20. The business has a fifty day moving average of C$0.09 and a 200 day moving average of C$0.06.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- What Does Downgrade Mean in Investing?
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- How to Choose Top Rated Stocks
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
